Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 9, 2026Cancer Epidemiology Biomarkers & Prevention

Racial/ethnic disparities in risk of second primary malignancies among Diffuse Large B-cell Lymphoma survivors.

View Full Paper
Ask AI
Bookmark
Share

Authors

PAPragati AdvaniNational Institutes of HealthHYHan YuQingdao UniversityKCKayla CatalfamoRoswell Park Comprehensive Cancer Center

Discussion

Loading...

Member takes

Implication

Randomized trial investigates second primary malignancy risks in diffuse large B-cell lymphoma survivors, revealing significant racial disparities.

Key Points

  • To explore the risk of second primary malignancies among diffuse large B-cell lymphoma survivors by race/ethnicity.
  • Analyzed data from 68,358 DLBCL survivors using Surveillance, Epidemiology and End Results (SEER) program.
  • Calculated standardized incidence ratios (SIRs) and 95% confidence intervals for second primary malignancy risk.
  • Examined variations in risk by race/ethnicity for hematological and solid malignancies.
  • Identified 6,261 second primary malignancies post-DLBCL, with an overall 1.2-fold increased risk (95% CI=1.16-1.22).
  • Asian/Pacific Islanders and Hispanics showed higher SPM risk than White or Black counterparts (Pheterogeneity<0.001).
  • Elevated risks were noted for specific cancers: anal cancer (Black SIR=9.29, Hispanic SIR=8.55) and acute non-lymphocytic lymphoma in non-White groups.

Cite This Study

Advani et al. (2026) studied this question.

synapsesocial.com/papers/6a782d862e1896536c840b41https://doi.org/10.1158/1055-9965.epi-26-0672
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pharmacogenetics as a Future Tool to Risk-Stratify Breast Cancer Patients According to Chemotoxicity Potential from the Doxorubicin Hydrochloride and Cyclophosphamide (AC) Regimen2025 · 9 citations
  2. 2Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence2014 · 3,621 citations
  3. 3Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: Recent advances and emerging therapies2025 · 34 citations
  4. 4Second Malignancy Risks After Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: Differences by Lymphoma Subtype2010 · 206 citations